Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531869 | 0.76 | CYP1B1 (0.41) | ALDH1A1POLB | |
| SCHEMBL24317634 | 0.76 | CYP1B1 (0.41) | ALDH1A1POLB | |
| SCHEMBL24329218 | 0.76 | SLC22A12 (0.35) | SLC22A12ALOX5ALDH1A1POLB | |
| SCHEMBL29583096 | 0.76 | SLC22A12 (0.35) | SLC22A12ALOX5ALDH1A1POLB | |
| SCHEMBL27671105 | 0.70 | LMNA (0.37) | ALOX5ALDH1A1POLBCA12CA1 | |
| SCHEMBL12196093 | 0.64 | ALOX5 (0.42) | ALOX5ALDH1A1POLBCYP1A2CYP2C19 | |
| SCHEMBL30839691 | 0.64 | NPC1 (0.32) | SLC22A12ALOX5ALDH1A1POLB | |
| SCHEMBL21706214 | 0.62 | NOTUM (0.38) | POLB | |
| SCHEMBL22927604 | 0.62 | NOTUM (0.38) | POLB | |
| SCHEMBL28942747 | 0.61 | KCNA5 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |